I-JYMed iklonyeliswe ngelungelo lobunikazi laseYurophu ngendlela yayo yokuqamba ye-Liraglutide. Lesi sigameko esiyingqopha-mlando sigqamisa ubuholi bethu obuqhubekayo ku-peptide R&D ne-IP. Le patent imele inqubo entsha yokuhlanganiswa kwe-liraglutide, engagcini nje ngokuqinisekisa isivuno esizinzile kodwa futhi enciphisa ngokuphawulekayo ukwakheka kokungcola kwe-racemic [D-Thr^5] -Liraglutide, efana kakhulu nomkhiqizo oqondiwe. Lokhu okusha kuthuthukisa ikhwalithi yomkhiqizo iyonke.

Ukutholwa kwaleli lungelo lobunikazi laseYurophu kukhombisa amakhono aphelele e-R&D enkampani, kuqinise ngokwengeziwe izinzuzo zayo zobuchwepheshe. Ifaka isandla ekuqiniseni ukuncintisana okungumongo kwe-JYMed nokwandisa ubukhona bayo ezimakethe zomhlaba. Ukwengeza, iqinisa izinzuzo zempahla yengqondo yenkampani, isiza ukugcina nokuthuthukisa ukuncintisana kwayo ezimakethe zomhlaba.

I-Hubei JXBio Pharmaceutical Co., Ltd, inkampani ephethwe yi-Shenzhen JYMed Technology Co., Ltd, isanda kuthola Isaziso Sokugunyazwa Kwemakethe Ye-Oxytocin Active Pharmaceutical Ingredient (API) esikhishwe yi-National Medical Products Administration (NMPA) yase-China.

Lokhu kugunyazwa kubonisa ukuthi i-JXBio's oxytocin API ihlangabezana nezidingo zobuchwepheshe ezilawulayo ezibekwe uhlelo lukazwelonke lokuhlola izidakamizwa. Kuphawula ingqophamlando ebalulekile enkampanini, ithuthukisa futhi iphothifoliyo yomkhiqizo wayo futhi inikeze isisekelo esiqinile sokwanda kwemakethe emkhakheni we-oxytocin.
MAYELANA no-JYMED
I-JYMed yinkampani yobuchwepheshe obuphezulu be-biopharmaceutical egxile ocwaningweni oluzimele, ekuthuthukisweni, ekukhiqizweni nasekuthengisweni kwemikhiqizo esekwe ku-peptide, kanye nezinsizakalo zokuthuthukiswa kwezinkontileka kanye nenhlangano yokukhiqiza (CDMO). Inkampani izibophezele ekuhlinzekeni ama-API wekhwalithi ephezulu we-peptide kanye nezixazululo ezenziwe ngezifiso kumakhasimende omhlaba. Iphothifoliyo yomkhiqizo wayo ihlanganisa inqwaba ye-peptide APIs, enemikhiqizo ewumgogodla efana ne-Semaglutide ne-Terlipressin esekuqedile ukufakwa kwe-US FDA DMF.

Inkampani engaphansi kwayo, i-Hubei JXBio Pharmaceutical Co., Ltd., isebenzisa imigqa yokukhiqiza ye-peptide yesimanjemanje ethobela izindinganiso ze-cGMP ezibekwe yi-US FDA, European EMA, kanye ne-NMPA yaseChina. Lesi sikhungo sihlanganisa imigqa yokukhiqiza eyi-10 emikhulu neyisivivinyo futhi sisungule uhlelo oluqinile lokulawulwa kwekhwalithi yezemithi (QMS) kanye nohlelo lokuphatha impilo nokuphepha kwemvelo (EHS). Lokhu kuqinisekisa ukuthi yonke inqubo, kusukela ku-R&D kuya ekukhiqizweni, ihlangabezana nezindinganiso zomhlaba wonke eziphakeme kakhulu. Le nkampani iphumelele ngempumelelo ukuhlolwa kokuthobela i-GMP yi-FDA yase-US kanye ne-NMPA yase-China futhi iye yaqashelwa izinkampani ezihola phambili zemithi yomhlaba wonke ngobuhle bayo bokuphatha i-EHS, okubonisa ukuzibophezela kwayo okuvelele kukhwalithi, ukuphepha, kanye nokuzibophezela kwemvelo.

Izindawo Zebhizinisi Eziyinhloko:Ukubhaliswa nokuhambisana kwe-peptide API yasekhaya neyamazwe ngamazwe,Ama-peptide ezilwane kanye nezimonyo,Izinsizakalo ze-peptide zangokwezifiso, ezifaka izixazululo ze-CRO, i-CMO, ne-OEM,I-Peptide-drug conjugates (PDCs), okuhlanganisa i-peptide-radionuclide, i-peptide-molecule encane, i-peptide-protein, kanye ne-peptide-RNA yokwelapha.

IMIKHIQIZO EYINHLOKO

Ukuze uthole imininingwane eyengeziwe ngemikhiqizo yethu, sicela usithinte.

I-Global API kanye nemibuzo yezimonyo: Inombolo yocingo: +86-15013529272;

Ukubhaliswa kwe-API & Izinsizakalo ze-CDMO (imakethe yase-USA EU）: +86-15818682250

I-imeyili:jymed@jymedtech.com

Ikheli: Floors 8 & 9, Building 1, Shenzhen Biomedical Innovation Industrial Park, 14 Jinhui Road, Kengzi Subdistrict, Pingshan District, Shenzhen